BioCentury | May 12, 2020
Product Development

May 11 Quick Takes: Genfit’s elafibranor misses in NASH Phase III; plus AstraZeneca, Merck, Protalix and TolerogenixX

Genfit’s PPAR agonist fails to resolve NASH  Genfit S.A. (Euronext:GNFT; NASDAQ:GNFT) fell $10.88 (49%) to $11.22 in after-hours trading Monday after reporting that dual PPARα/δ agonist elafibranor missed the primary endpoint of the Phase III...
BioCentury | May 9, 2020
Product Development

A guide to COVID-19 vaccine modalities in the clinic

Of the more than 90 vaccines in development for COVID-19, at least nine -- spanning nucleic acid, viral vector-based and inactivated vaccines -- are in clinical testing. During infection with SARS-CoV-2, the host proteins ACE2...
BioCentury | Feb 1, 2020
Tools & Techniques

Rosenberg study opens wider door to personalized TCR therapies for cancer

A new study from TIL pioneer Steve Rosenberg adds to the momentum of personalized T cell therapies by suggesting blood can be as good a source of neoantigen-specific TCRs as tumor tissue. The results, which...
BC Extra | Jan 29, 2020
Preclinical News

Rosenberg study highlights opportunity for blood-based take on TILs against mutant p53

A new study from TIL pioneer Steve Rosenberg adds to the momentum of blood-derived personalized T cell therapies by showing concordance between T cell responses against common p53 mutations in patients’ solid tumors and those...
BC Innovations | Aug 15, 2019
Product Development

Adaptive is surfing a wave of enthusiasm in disease detection, betting on the immune system

Adaptive’s float to more than $5 billion after its June IPO is largely based on its ambition to compete with the likes of Grail and Guardant in early diagnosis of cancer and other diseases by...
BC Innovations | Jul 25, 2019
Translation in Brief

Neoantigens in pediatric ALL could lead to cell-based therapies

Despite low tumor mutation load, strong immune responses against predicted neoantigens suggest opportunities to develop immunotherapies for pediatric acute lymphoblastic leukemia. The oncology field is increasingly turning to neoantigens -- non-self antigens arising from mutations...
BC Extra | May 1, 2019
Preclinical News

May 1 Preclinical Quick Takes: MD Anderson, Sana, Sigilon

MD Anderson findings could make radiation possible for pancreatic cancer  Researchers at University of Texas MD Anderson Cancer Center reported findings suggesting that HIF-PH inhibition could help prevent radiation-induced GI injury, the main factor that...
BC Innovations | Jan 17, 2019
Emerging Company Profile

Zelluna’s solid TCR plans

Zelluna Immunotherapy A/S is using a portfolio of HLA class II-restrictive TCRs to develop autologous cell therapies that could unleash a broader immune attack on solid tumors than other TCR-based cell therapies in development. CEO...
BC Innovations | Jan 3, 2019
Translation in Brief

Neo opportunities in glioblastoma

Phase I results from a consortium led by BioNTech AG and Immatics Biotechnologies GmbH convinced both companies that personalized immunotherapies can turn on T cell activity in glioblastoma, an immunologically "cold" cancer. The study is...
BC Innovations | Jan 3, 2019
Distillery Techniques

Assays and screens; other

TECHNOLOGY: Cellular assays; computational models A computational method to predict HLA peptide presentation could help identify neoantigens for cancer immunotherapy. The deep learning model was trained on a data set to identify the relationships between...
Items per page:
1 - 10 of 113